Cannabis and Pregnancy

Cannabis use during pregnancy is a topic that sits at a complex intersection of public health, medical science, legal policy, and personal decision-making. As cannabis legalization continues to expand across the United States and globally, more people are encountering conflicting messages about whether cannabis is safe to use while pregnant. Some dispensary staff, online forums, and even well-meaning friends may suggest that cannabis is a "natural" remedy for morning sickness or pregnancy anxiety. However, the overwhelming consensus among medical professionals and researchers is clear: cannabis use during pregnancy is not considered safe.

This guide is intended to provide comprehensive, evidence-based information about what we currently know regarding cannabis and pregnancy — including the biological mechanisms by which cannabis affects fetal development, the potential risks to both mother and child, and the legal landscape surrounding prenatal cannabis use. Our goal is to educate, not to judge, recognizing that many pregnant individuals face genuine challenges such as severe nausea, anxiety, and chronic pain that may drive them toward seeking relief through cannabis.

Why Cannabis Use During Pregnancy Is Rising

Several societal and cultural factors have contributed to increasing rates of cannabis use during pregnancy. The rapid legalization of cannabis across U.S. states has reduced the perceived risk of the substance. Many people now view cannabis as a wellness product rather than a drug with potential harms. Additionally, the marketing of cannabis products — including CBD oils, edibles, and tinctures — as natural health remedies has created confusion about safety, particularly in the absence of clear, universally publicized medical warnings comparable to those associated with alcohol.

The primary driver reported by pregnant cannabis users is symptom management. Nausea and vomiting of pregnancy (NVP), particularly hyperemesis gravidarum (HG) in its most severe form, can be debilitating. When first-line interventions such as dietary changes or over-the-counter remedies fail, some pregnant individuals turn to cannabis — often without consulting their healthcare provider.

The Legal and Medical Landscape

From a legal standpoint, cannabis remains a Schedule I controlled substance under federal law in the United States, meaning it is classified as having no accepted medical use and a high potential for abuse at the federal level. However, state laws vary widely. Understanding the legal status of cannabis in your state is critical, particularly for pregnant individuals, as some states have enacted mandatory reporting laws that require healthcare providers to report prenatal cannabis use to child protective services. This has significant implications for how pregnant individuals disclose their cannabis use to healthcare providers.

To understand the risks of cannabis use during pregnancy, it is essential to understand the biology of how cannabis interacts with fetal development. The human endocannabinoid system (ECS) plays a critical role in fetal neurodevelopment, and exposure to exogenous cannabinoids — particularly THC — can disrupt this delicate biological process with potentially long-lasting consequences.

The Endocannabinoid System and Fetal Development

The endocannabinoid system is one of the earliest systems to develop in the human embryo. Endocannabinoid receptors (CB1 and CB2) are present in the developing brain as early as the first trimester and play a crucial regulatory role in neuronal migration, synaptogenesis (the formation of synaptic connections), and overall brain architecture. When a pregnant person consumes cannabis, THC — the primary psychoactive compound — crosses the placental barrier and binds to these same receptors in the fetal brain, potentially disrupting the natural signaling processes that guide healthy neurodevelopment.

Research published in journals such as JAMA Pediatrics and Neurotoxicology and Teratology has shown that prenatal THC exposure is associated with alterations in brain structure and function that can persist into childhood and adolescence. These include differences in attention, executive function, memory, and behavioral regulation.

Placental Transmission of THC

The placenta, which serves as the primary interface between maternal and fetal circulation, does not provide a complete barrier against THC. Studies using animal models and human placental tissue have demonstrated that THC readily crosses the placental barrier. Furthermore, THC is highly lipophilic (fat-soluble), meaning it can accumulate in fetal fatty tissues over time. The fetal liver, which is still developing, has a limited capacity to metabolize THC efficiently, leading to prolonged exposure at the cellular level. This is distinct from how THC affects an adult's body, where a mature liver and established metabolic pathways facilitate more rapid clearance — a factor also relevant to cannabis drug testing timelines.

Effects on Fetal Growth and Birth Outcomes

Beyond neurological effects, prenatal cannabis exposure has been associated with a range of adverse birth outcomes. These include:

• Low birth weight: Infants born to cannabis-using mothers are more likely to be small for gestational age.
• Preterm birth: Some studies have found a correlation between cannabis use and increased risk of preterm labor.
• Stillbirth: Research published in the journal Obstetrics & Gynecology found that cannabis use was associated with a significantly higher risk of stillbirth, even after controlling for tobacco use.
• NICU admission: Newborns exposed prenatally to cannabis may require neonatal intensive care unit admission at higher rates.
• Neonatal abstinence syndrome: Some research suggests that infants exposed to cannabis in utero may exhibit withdrawal-like symptoms after birth.

One of the most concerning aspects of prenatal cannabis exposure is not limited to birth outcomes — it extends into the long-term cognitive, behavioral, and psychological development of children. Longitudinal studies that follow children from birth through adolescence have provided some of the most compelling evidence for the lasting impact of in utero cannabis exposure.

Cognitive and Behavioral Outcomes in Children

The Ottawa Prenatal Prospective Study (OPPS), one of the longest-running studies on prenatal cannabis exposure, has tracked children for over three decades. Findings from this and similar studies suggest that children with prenatal cannabis exposure demonstrate: